The lead drug candidate targets CD40-expressing cells, and with the simultaneous delivery of peptide cargo, the therapeutic intervention leads to a robust specific anti-tumor immune response in vivo, with an improved safety profile in comparison to the reference anti-CD40 antibody selicrelumab. Here, CD40 is linked to neoplasm.